Autosomal dominant polycystic kidney disease kinin-system in polycystic kidney disease of the rat.
nostic value, and their identification could help establish
Results. Urine levels of kallikrein were increased threefold in 9-month-old PKD, and BK excretion was increased tenfold therapeutical strategies aimed at delaying the progresin 3-month and 30-fold in 9-month-old PKD compared to agesion of renal failure in subjects with ADPKD. Impormatched SD rats. Blood pressure in 9-month-old PKD rats was tantly, hypertension and proteinuria have been implidecreased to the same degree by ramipril and HR 720. In cated in a more severe disease progression in ADPKD contrast, only ramipril and HOE 140 significantly reduced propatients [4] [5] [6] . This situation is, however, not unique to teinuria and albuminuria, independent from creatinine clearance. This effect was accompanied by an increased excretion ADPKD, but is observed in a large number of kidney of bradykinin. The B1 receptor antagonist had no influence on diseases. Lowering of arterial blood pressure and/or profunctional renal parameters. teinuria therefore remains a primary therapeutical goal.
Conclusions. The present study demonstrates an age-depenIn most of these diseases, the renin-angiotensin-system dent activation of the renal KKS in rats with polycystic kidney (RAS) plays a seminal role with respect to arterial hyperdisease. The bradykinin B2-receptor is involved in the pathotension, regulation of glomerular filtration rate (GFR), genesis of proteinuria, independent from systemic blood pressure or creatinine clearance. The antiproteinuric effect of ramidevelopment of proteinuria, and progression of chronic pril in this model is angiotensin II-independent and related to renal failure. This concept has been demonstrated by its influence on the renal KKS.
the nephroprotective effect of pharmacological blockade of the RAS in diabetic nephropathy [7] , chronic allograft nephropathy [8] , and remnant kidney model [9] , to name only a few.
other neurohumoral systems. One of them is the kallikrein-kinin-system (KKS). Comparable to the RAS, it  2002 by the International Society of Nephrology is composed of a series of potent vasoactive and proinresected. Two weeks later, uninephrectomy of the right flammatory molecules. An involvement in inflammatory kidney was performed. Animals were included in the processes has been demonstrated both in vitro and in experiments at the age of 9 months. vivo [10, 11] . The KKS also is activated in the advanced Rats were housed in metabolic cages twice for 24 stage of diabetic nephropathy in streptozotocin (STZ)-hours. During the first 24 hours urine was collected in treated rats, a condition characterized by proteinuria and conventional tubes for determination of volume, creatidecreased GFR [12] . Given the pronounced tubulointernine, sodium, protein, prekallikrein and kallikrein. A stitial inflammation, the development of progressive reblood sample was obtained for determination of creatinal failure and proteinuria, and the high incidence of nine, sodium, plasma renin activity, prekallikrein and arterial hypertension, the KKS may be activated in pakallikrein. Blood pressure was measured by tail plethystients with ADPKD. Thus far, however, this has not been mography, for which all animals had been previously systematically investigated.
trained. After 24 hours of rest the animals were again The (cy/ϩ) rat is an animal model for ADPKD that housed in metabolic cages for 24 hours. Urine for detershares many clinical and histological features with humination of bradykinin was collected in tubes containing man ADPKD [13] . It provides a suitable tool to investipure ethanol to arrest kinin formation and degradation. gate the activity of the RAS and the KKS and their Volume of ethanol in the collection tube was chosen contribution to functional renal changes observed during such that the concentration of urine at the end of the the progression of renal failure. Their respective roles collection period did not exceed 30% of total volume. in regulation of blood pressure and proteinuria were investigated in the present study by short-term applica- period. Before and after the treatment period, blood Germany, were used in the experiments. Animals were samples were obtained for determination of creatinine, included in the study at the age of three and nine months. sodium and plasma renin activity. Urine was collected Heterozygous rats were detected by manual palpation for determination of creatinine, sodium and protein. In of the polycystic kidneys. All experiments were peraddition, urinary excretion of prekallikrein, kallikrein, formed in conscious animals. Environmental conditions and bradykinin was determined before and after adminwere kept constant: temperature 20ЊC, air humidity 65% istration of each drug in 9-month-old PKD rats. Systolic and a day/night cycle of 12 hours each. All rats were blood pressure was measured by tail plethysmography. allowed free access to tap water and to a standard laboratory rat chow containing 19% protein (Altromin 1324, Measurement of sodium, creatinine and protein in Lage, Germany). All animal experiments were conserum and urine ducted in accordance with the NIH Guide for the Care Concentration of sodium in serum and urine was deand Use of Laboratory Animals.
termined by use of a flame photometer (FLM-3; Radiometer, Copenhagen, Denmark). Concentrations of creatiExperimental protocol 1: KKS and ADPKD nine in serum and urine were measured by standardized Five groups of animals were studied: group 1 (3-monthcolorimetric method (Hitachi Autoanalyser; Boehringer old PKD; N ϭ 15), group 2 (3-month-old SD; N ϭ 9), Mannheim, Mannheim, Germany) and are expressed as group 3 (9-month-old PKD; N ϭ 26), group 4 (9-monthmg/dL. Urinary protein concentration was determined old SD; N ϭ 18), and group 5 (9-month-old SD with renal following the method of Coomassie after centrifugation mass reduction; N ϭ 8). Renal ablation was performed as of urine samples. Values for creatinine clearance and previously described [14] . Briefly, in 6-month-old SD fractional sodium excretion were calculated using stanrats, the left kidney was exteriorized through a dorsal approach, and the upper and lower poles were surgically dard formulas.
Measurement of albumin in urine Drugs
Ramipril, HR 720, and HOE 140 were a generous gift Urinary albumin was measured using a commercially available kit (Nephrat; Exocell, Inc., Philadelphia, PA, from Professor B.A. Schö lkens (Hoechst AG, Frankfurt/ Main, Germany). Des-Arg9-[Leu8]-bradykinin was pur-USA). Urine samples were added to wells bearing antirat-albumin on the solid phase. After 20 minutes at room chased from Sigma-Aldrich (Deisenhofen, Germany). temperature rat-albumin-HRP conjugate was added (withData calculation and statistical evaluation out washing), and a 45 minute incubation was completed. Wells were washed sixfold with phosphate-buffered saAll data are expressed as means Ϯ SEM. Differences line (PBS; Gibco BRL, Paisley, Scotland, UK)/0.05% between groups were assessed by one-way analysis Tween 20 (Sigma, St. Louis, MO, USA), and bound of variance (ANOVA) when appropriate. Two-tailed conjugate was analyzed using TMB (3,3Ј,5,5Ј-tetramethpaired t test with Bonferroni's correction for adjustment ylbenzidine) substrate solution. The chromogenic reacfor multiple testing was used after ANOVA for further tion was stopped with diluted sulfuric acid, and color pair-wise comparison of the groups. Effects of treatment intensity determined using a microplate reader set at regimens were assessed by the Student t test for paired 450 nm.
values. Statistical significance was defined as P Ͻ 0.05.
Measurement of plasmin renin activity RESULTS

Plasma renin activity was determined by radioimmu-
KKS and ADPKD noassay as described by Fyhrquist et al [15] . Plasma renin values are expressed as ng angiotensin-1 (Ang-1)/mL/h.
Creatinine clearance was lower in 3-month-old PKD compared to 3-month-old SD (P Ͻ 0.05) and lower in Measurement of prekallikrein and kallikrein in urine 9-month-old PKD and 9-month-old SD with renal ablaActivity of prekallikrein and kallikrein was detertion compared to 9-month-old SD (P Ͻ 0.05, respecmined following the method described by Amundsen et tively), whereas there was no difference between 9-al [16]. The chromogenic peptide substrate H-D-Valmonth-old PKD and rats with remnant kidney. CreatiLeu-Arg-p-nitroanilide (S-2266; Haemochrom Diagnosnine clearance was reduced in 9-month-old SD in comtika, Essen, Germany) was used in this assay, and extincparison to the young SD (P Ͻ 0.05), as was the clearance tion was measured photometrically at 405 nm. Each samin old PKD in comparison to young PKD rats (P Ͻ 0.05; ple was compared to a negative control sample in which Table 1 ). kallikrein was inhibited by the addition of aprotinine Fractional sodium excretion did not differ between (100 KIU/mL). Activity of kallikrein in urine was derived 3-month-old SD and PKD, but was significantly higher from extinction difference between the two samples and in 9-month-old PKD compared to age-matched SD (P Ͻ expressed as units per liter (U/L). One unit is the amount 0.05). SD with reduced renal mass showed a significant of kallikrein that converts 1 mol of substrate under higher fractional sodium excretion than 9-month-old standardized conditions. PKD animals (P Ͻ 0.05; Table 1 ). Plasma renin activity did not differ between 3-monthMeasurement of prekallikrein and kallikrein in plasma old SD and PKD, whereas it was suppressed in 9-monthEnzymatic activity of plasma prekallikrein and kalliold PKD compared to both 9-month-old SD and rats krein was determined with the amidolytic assay dewith reduced renal mass (P Ͻ 0.01, respectively). Proscribed by Gallimore and Friberger [17] . In this assay the teinuria did not differ between young SD and PKD, chromogenic substrate H-D-Pro-Phe-Arg-p-nitroanilide but was significantly increased to the same level in both (S2302; Haemochrom Diagnostika, Essen, Germany) 9-month-old PKD and rats with reduced renal mass in was used.
comparison to 9-month-old SD (P Ͻ 0.01, respectively). Albuminuria was significantly increased in PKD and neMeasurement of bradykinin in urine phrectomized rats compared to age-matched SD (P Ͻ 0.05, respectively). After ethanol extraction and high-pressure liquid chromatography (HPLC) separation (ODP 50; AsahiSystolic blood pressure did not significantly differ between the four groups of SD and PKD (although there Pak) the concentration of bradykinin was measured using the radioimmunoassay developed in our laboratories was a trend toward higher values in older rats), but was elevated in rats with renal ablation (P Ͻ 0.05, compared [18] . Highly sensitive and specific antisera were raised against BK. to 9-month-old SD and PKD; Table 1 ). Plasma levels for prekallikrein and kallikrein did not BK displayed a cross-reactivity of 24%. All other natural kinin derivatives showed a cross-reactivity of less differ between the four groups of SD and PKD, but were significantly higher in SD with remnant kidney (P Ͻ than 1%. Values for creatinine clearance (mL/min/100 g), fractional sodium excretion (%), plasma renin activity (ng Ang I/mL/h), proteinuria (mg/24 h), albuminuria (mg/24 h), and systolic blood pressure (mm Hg) in 3-and 9-month-old SD and PKD and 9-month-old 5/6 nephrectomized SD. Data are presented as means Ϯ SEM; N ϭ number of animals. Values for plasma prekallikrein (U/mL), plasma kallikrein (U/L), urine prekallikrein (mU/24 h), urine kallikrein (mU/24 h), and urine bradykinin (ng/24 h) in 3-and 9-month-old SD and PKD and 9-month-old 5/6 nephrectomized SD. Data are presented as means Ϯ SEM. N ϭ number of animals.
a P Ͻ 0.05 compared to 3-month-old SD or PKD b P Ͻ 0.05 compared to age-matched SD c P Ͻ 0.05; 5/6 Nx compared to 9-month-old SD d P Ͻ 0.05; 5/6 Nx compared to 9-month-old PKD e P ϭ 0.06 compared to 9-month-old SD 0.05, compared to 9-month-old SD and PKD; Table 2 ).
Effect of ramipril, HR 720, HOE 140, and des-Arg9-[Leu8]-BK on renal function in PKD Urinary excretion of prekallikrein was reduced in 9-monthold SD and PKD in comparison to young controls (P Ͻ
No influence on creatinine clearance, fractional so-0.05, respectively), whereas it did not differ between SD dium excretion, and urine volume was found in the differand PKD. Urinary prekallikrein was further reduced in ent treatment groups (Table 3 ; data only shown for creatrats with reduced renal mass when compared to old PKD inine clearance). (P Ͻ 0.05). Urine excretion of kallikrein was markedly Plasma renin activity was markedly increased by ramielevated in old PKD compared to both young PKD and pril and HR 720 in all groups (P Ͻ 0.05). Although this old SD (P Ͻ 0.05, respectively), whereas excretion in increase was numerically higher in ramipril-treated rats, partially nephrectomized rats did not differ from 9-monthit did not statistically differ from animals treated with old SD (Table 2) .
HR 720. Bradykinin-receptor blockade had no influence Urinary bradykinin excretion was increased tenfold on PRA (Table 4) . in 3-month-old PKD and 30-fold in 9-month-old PKD Systolic blood pressure was not influenced in 3-monthcompared to age-matched SD (P Ͻ 0.05, respectively).
old SD and PKD (Fig. 1) , whereas a significant decrease In remnant kidney there was a trend toward higher brawas observed in 9-month-old PKD and 9-month-old SD dykinin levels in comparison to old SD (P ϭ 0.06).
treated with ramipril and HR 720 (P Ͻ 0.05). HOE Chromatographic separation by HPLC of the urinary 140 and des-Arg9-BK had no effect on systolic blood bradykinin fraction in 9-month-old PKD revealed a secpressure. ond activity peak. This peak could be identified as deRamipril and HOE 140 significantly reduced proteinsArg9-bradykinin, or T-kinin. Its concentration made uria in 3-and 9-month-old PKD, whereas ramipril and up 13% of total bradykinin concentration in old PKD.
HOE 140 had no influence on proteinuria in 3-and T-kinin could not be demonstrated by HPLC in any of 9-month-old SD. HR 720 and des-Arg9-BK had no statistically significant effect on the proteinuria in all groups the other investigated groups (data not shown). (N ϭ 10, each group) .
3-month-old PKD; (᭛) 3-month-old SD. Proteinuria was significantly Symbols are: (ᮀ) 9-month-old PKD; (᭝) 9-month-old SD; (᭺) 3-monthreduced in 3-and 9-month-old PKD after treatment with ramipril and old PKD; (᭛) 3-month-old SD. Systolic blood pressure was significantly HOE 140 (*P Ͻ 0.05). Data are presented as means Ϯ SEM. reduced in 9-month-old PKD and SD after treatment with ramipril and HR 720 (*P Ͻ 0.05). Data are presented as means Ϯ SEM. (Fig. 2) . Similarly, albuminuria was significantly lowered
DISCUSSION
The present study demonstrates an age-dependent inby ramipril and HOE 140 only in the 3-and 9-monthcrease in the activity of the renal KKS in the Han:SPRD old PKD rats (Fig. 3) . rat model of ADPKD, which paralleled the development Ramipril had no influence on urinary excretion of preof progressive renal failure. and kallikrein, whereas bradykinin excretion was markIn addition to a marked increase in urinary excretion edly increased (Table 5 ). HR 720 had no effect on these of kallikrein and bradykinin, we showed that 9-monthparameters. Selective bradykinin-B2 receptor blockade old PKD rats excrete T-kinin (desArg9-bradykinin). This increased excretion of pre-and kallikrein as well as of inflammatory peptide was first isolated in rat plasma [19, bradykinin, whereas B1 receptor blockade decreased excretion of all these molecules. 20], where it is cleaved from its biosynthetic precursor cantly decreased by treatment with ramipril and HOE 140. Angiotensin II receptor-blockade had no effect on protein excretion, despite an equal suppression of the RAS, as indicated by a significant increase of PRA and a blood pressure reduction equal to ramipril. Thus, an angiotensin II-independent pathway is responsible for the proteinuria in PKD rats. The role of the KKS with respect to proteinuria has been studied in several experiments. Infusion of kallikrein into the renal artery of dogs causes proteinuria, which can be reversed by the kallikrein inhibitor aprotinin [24] . Bradykinin and related kinins are potent stimu- in rat models with normal or suppressed plasma renin levels, where effects of ACE inhibition were related to the interference with the KKS and not to inhibition of T-kininogen. Urinary kinins in Sprague-Dawley rats angiotensin II production. Hutchison, Webster and Jaffa have been identified as bradykinin, whereas kallidin, arshowed that aprotinin could prevent the reduction of ginyl-BK, or T-kinin could not been detected [21] . Our albuminuria induced by an ACE inhibitor in passive study is, to our knowledge, the first demonstration of a Heymann nephritis [27] . The administration of phosurinary excretion of T-kinin in rats.
phoramidon, which potentiates the kinin activity by inhiPrevious experimental studies have reported a rebition of the neutral endopeptidase, reduced albuminduced excretion of kallikrein in acute renal failure [22] , uria to a similar extent as an ACE inhibitor. The anti-glomerular basement membrane nephritis and amangiotensin II receptor antagonist losartan, on the other inonucleoside nephrosis [22] , unilateral nephrectomy hand, decreased systolic blood pressure without any [23] , and diabetic nephropathy [12] . No kallikrein inhibichange in albuminuria [28] . tors could be found in the urine of diseased animals, and
In the present study only HOE 140 decreased proteinit was concluded that tubular damage and/or destruction uria and albuminuria to the same extent than the ACE of kallikrein-producing interstitial cells were the most inhibitor. This effect was independent from any influence likely cause of decreased urinary kallikrein excretion.
on systemic blood pressure and glomerular filtration rate. Compared to rats with polycystic kidney disease, animals Selective B1 receptor blockade had no effect on urinary subjected to renal mass reduction in our study excreted protein excretion, demonstrating that the B2-receptor significantly less kallikrein and also less bradykinin. Beplays a seminal role in the pathogenesis of proteinuria cause creatinine clearance and proteinuria were virtually and albuminuria in PKD rats. This hypothesis is further identical in these animals, our findings strongly suggest supported by the demonstration of T-kinin in urine of disease-specific differences in the activity of the renal old PKD rats, given the fact that this molecule acts as kallikrein-kinin-system. an agonist at the B2 receptor [29, 30] , where it is 200-The treatment of polycystic kidney rats with drugs times more active than at the B1 receptor. that interfere at different levels with the RAS and the Both HOE 140 and ramipril increased urinary excre-KKS provides important new insights in the pathophysition of bradykinin, suggesting that the antiproteinuric ology of PKD. Both ACE inhibitors and angiotensin IIeffect of these drugs is mediated via stimulation of the type 1 receptor antagonists markedly reduced systolic non-blocked B1 receptor. However, the mechanism of blood pressure to the same degree in 9-month-old PKD increased bradykinin excretion fundamentally differs berats, whereas bradykinin B1-and B2-receptor antagotween icatibant and ramipril. Inhibition of the ACE, nists had no effect. Systemic blood pressure regulation which is identical to kininase II, decreases bradykinin in PKD therefore depends on the action of angiotensin degradation [31] . In contrast, no effect of ramipril on II, despite a suppressed plasma renin activity in these urinary excretion of prekallikrein and kallikrein was obanimals [13] . The KKS obviously does not play a role in served, which confirms previous studies in other animal blood pressure regulation in polycystic kidney disease models of chronic nephropathy [32, 33] . The increased rats.
kallikrein excretion observed after treatment with HOE 140 may be due to the inhibition of a recently described In contrast, proteinuria and albuminuria were signifi- Urine prekallikrein (mU/24 h), kallikrein (mU/24 h), and bradykinin (ng/24 h) in 9-month-old PKD (N ϭ 6, each treatment cycle) before and after treatment with 2 mg/kg/day ramipril, 10 mg/kg/day HR 720, 2 ϫ 200 g s.c. HOE 140, or 2 ϫ 250 g des-Arg9-[Leu8]-BK for four days. Data are presented as means Ϯ SEM.
a P Ͻ 0.05, b 0.01; treatment effect compared to baseline value therapy with enalapril and losartan on the rate of progression of
